The Value of [18F]FDG PET/CT Imaging in Prognostic Evaluation of Mucosal Melanoma

Brief summary (registry, in English)

This project will target patients with histopathologically diagnosed mucosal melanoma using \[¹⁸F\]FDG PET/CT imaging for retrospective prognostic evaluation.The primary objective is to explore the value of \[¹⁸F\]FDG PET/CT imaging in the prognostic assessment of mucosal melanoma, and to determine the correlations between quantitative \[¹⁸F\]FDG PET parameters and progression-free survival (PFS) as well as overall survival (OS), so as to provide reference evidence for individualized treatment decision-making.

What you commit to

• Study type: Observational
• Participants enrolled: 68
• From 1 Jan 2021 to the primary completion date, 8 May 2025
• 1 site in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.